英科医疗科技股份有限公司（以下简称"公司"）第三届董事会、监事 会任期将于 2025 年 3 月 14 日届满，鉴于公司新一届董事会、监事会的选举 工作尚在筹备中，为确保公司相关工作的连续性及稳定性，公司董事会、监 事会换届选举工作将适当延期，公司董事会各专门委员会及公司高级管理人 员的任期亦相应顺延。 证券代码：300677 证券简称：英科医疗 公告编号：2025-023 英科医疗科技股份有限公司 关于公司董事会、监事会延期换届选举的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特此公告。 在公司董事会、监事会换届选举工作完成之前，公司第三届董事会、监 事会全体成员及高级管理人员将依照相关法律、法规和《英科医疗科技股份 有限公司章程》的有关规定继续履行职责。 公司董事会、监事会延期换届不会影响公司正常运营。公司将根据相关 工作进展情况，持续推进董事会和监事会的换届工作，并及时履行信息披露 义务。 英科医疗科技股份有限公司 董事会 2025 年 3 月 13 日 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-022 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第二十一次（定 期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东 大会，审议通过了《关于公司及子公司向银行申请授信额度及担保事 项的议案》。为满足公司及子公司的生产经营需要，公司及子公司拟 向银行等金融机构申请综合授信的额度以及金融衍生品交易风险限 额的总额（以下简称"授信额度"）不超过 300 亿元人民币，对其担 保总额不超过 300 亿元人民币，授权期限自公司 2023 年度股东大会 审议通过之日起至下一年度股东大会召开时止。具体内容详见刊登于 巨潮资讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请 授信额度及担保事项的公告》《2023 年度股东大会决议公告》（公告 编号：2024-036、2024-050）。 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-021 英科医疗科技股份有限公司 二、股东股份累计质押的情况 截至本公告披露日，刘方毅先生所持质押股份情况如下： | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股数量 | 持股比 | 累计质押数 | 占其所 | 占公司 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | | | 持股份 | 总股本 | 限售和冻 | | | | | 名称 | （股） | 例 | 量（股） | | | | 押股份 | 限售和冻结 | 押股份 | | | | | | 比例 | 比例 | 结、标记数 | | | | | | | | | | | | 比例 | 数量（股） | 比例 | | | | | | | | 量（股） | | | | 股东名称 是否为控股股东或 第一大股东及其一 致行动人 本次解除质 押股数 （股） 占其所 持股份 比例 占公司 总股本 比例 起始日 解除日期 质权 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-020 英科医疗科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 9 月 19 日召开第三届董事会第二十五次会议和第三届监事会第二十三 次会议，审议通过了《关于公司回购股份方案的议案》，同意公司使 用不低于人民币 8,000 万元（含本数）且不超过人民币 12,000 万元 （含本数）的自有资金，以集中竞价交易的方式回购部分公司股份（人 民币普通股（A 股）股票），用于实施员工持股计划及/或股权激励。 回购价格不超过人民币 26.61 元/股（含本数），回购股份的数量和金 额以回购期限届满时实际回购的股份数量和金额为准。回购股份的实 施期限为自公司第三届董事会第二十五次会议审议通过本次回购股 份方案之日起不超过 12 个月。具体内容详见公司分别于 2024 年 9 月 19 日、2024 年 9 月 20 日和 2024 年 10 月 31 日披露于巨潮资讯网 （www.cninfo.com.cn） ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-019 上海英科心电图医疗产品有限公司（以下简称"英科心电图"） 因经营需要，向中国农业银行股份有限公司上海奉贤支行（以下简称 "农业银行上海奉贤支行"）申请授信额度，公司为上述授信提供人 民币 1,350 万元的连带责任保证担保，并于近日与农业银行上海奉贤 支行签订了《最高额保证合同》。 本次担保进展情况如下表： 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第二十一次（定 期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东 大会，审议通过了《关于公司及子公司向银行申请授信额度及担保事 项的议案》。为满足公司及子公司的生产经营需要，公司及子公司拟 向银行等金融机构申请综合授信的额度以及金融衍生品交易风险限 额的总额（以下简称"授信额度"）不超过 300 亿元人民币，对其担 保总额不超过 300 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is a global leader in the disposable glove market, with significant advantages in technology, manufacturing processes, and cost management. It has six production bases and exports to over 120 countries, serving more than 10,000 clients. The company is expected to see rapid revenue growth due to capacity expansion and business development [5][13] - The global disposable glove market is expected to continue expanding, with a projected sales volume of 82.93 billion gloves and revenue of $13.6 billion by 2025. The nitrile glove segment is anticipated to maintain a leading growth rate post-pandemic, supported by increasing demand and improved supply dynamics [5][48] Summary by Sections Company Overview - The company focuses on disposable gloves, leveraging its competitive advantages in production technology, supply chain management, and brand strength. It aims to strengthen its leadership position in the personal protective equipment industry [13][14] Market Dynamics - The global disposable glove market has shown stable growth, with a CAGR of 14.8% in sales volume and 37.0% in revenue from 2017 to 2021. The nitrile glove segment has outpaced others, with a CAGR of 18.0% in sales volume and 48.6% in revenue during the same period [47][48] Production Capacity - As of 2023, the company's total production capacity for disposable gloves reached 79 billion units, with 48 billion units for nitrile gloves and 31 billion units for PVC gloves. The company has six production bases in China, ensuring a competitive edge in production efficiency [6][25] Financial Performance - The company reported a total revenue of 6.919 billion yuan in 2023, a year-on-year increase of 4.61%. The projected net profits for 2024, 2025, and 2026 are 1.345 billion, 1.580 billion, and 1.857 billion yuan, respectively, indicating a strong recovery and growth trajectory [7][24] Investment and Growth Strategy - The company has a robust investment strategy, with significant capital allocated to expand production capacity and enhance technological capabilities. The cash reserves and fixed asset investments are expected to support long-term growth and maintain competitive advantages in the capital-intensive glove industry [35][36]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is a global leader in the disposable glove market, with significant advantages in technology, manufacturing processes, and automated production facilities. It has six production bases and exports to over 120 countries, serving more than 10,000 customers. Revenue is expected to grow rapidly due to increased capacity and business expansion. The projected net profits for 2024-2026 are 1.345 billion, 1.580 billion, and 1.857 billion CNY respectively, with current P/E ratios of 12.1, 10.3, and 8.8, indicating relatively low valuations compared to peers [5][7]. Summary by Sections Company Overview - The company focuses on disposable gloves, leveraging its comprehensive competitive advantages. It was established in 2009 and listed in 2017, holding a leading market share in both domestic and international markets. The company is well-prepared to strengthen its leadership position in the disposable glove industry [13][14]. Market Growth - The global disposable glove market is expanding, with significant long-term growth potential. The sales volume is expected to reach 82.93 billion pieces and sales revenue to reach 13.6 billion USD by 2025. The nitrile glove segment continues to lead in growth post-pandemic, with a clear growth logic in the Chinese market [5][47][48]. Production Capacity - The company's total production capacity for disposable gloves reached 79 billion pieces in 2023, with nitrile gloves accounting for 48 billion pieces and PVC gloves for 31 billion pieces. The company has six production bases in China and maintains a high product quality with a defect rate of over 99% [6][25][29]. Financial Performance - The company reported total revenue of 6.919 billion CNY in 2023, a year-on-year increase of 4.61%. The net profit for the same year was 383 million CNY, down 39.1% year-on-year. However, the company is expected to see a significant recovery in profits in 2024, with projected revenues of 9.33 billion CNY and net profits of 1.345 billion CNY [7][24][26]. Research and Development - The company has been increasing its R&D investment, with R&D expenses accounting for 4.1% of total revenue. The number of R&D personnel has also grown significantly, indicating a commitment to innovation and efficiency in production processes [29][30]. Employee Incentives - The company has implemented stock incentive plans to align the interests of its core team with the company's goals, aiming to support its global marketing and manufacturing strategies [37][38].

证券代码：300677 证券简称：英科医疗 公告编号：2025-018 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第二十一次（定 期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东 大会，审议通过了《关于公司及子公司向银行申请授信额度及担保事 项的议案》。为满足公司及子公司的生产经营需要，公司及子公司拟 向银行等金融机构申请综合授信的额度以及金融衍生品交易风险限 额的总额（以下简称"授信额度"）不超过 300 亿元人民币，对其担 保总额不超过 300 亿元人民币，授权期限自公司 2023 年度股东大会 审议通过之日起至下一年度股东大会召开时止。具体内容详见刊登于 巨潮资讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请 授信额度及担保事项的公告》《2023 年度股东大会决议公告》（公告 编号：2024-036、2024-050）。 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-017 英科医疗科技股份有限公司 关于公司及子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"或"英科医疗"） 于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第 二十一次（定期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东大会，审议通过了《关于公司及子公司向银行申请授信额度 及担保事项的议案》。为满足公司及子公司的生产经营需要，公司及 子公司拟向银行等金融机构申请综合授信的额度以及金融衍生品交 易风险限额的总额（以下简称"授信额度"）不超过 300 亿元人民币， 对其担保总额不超过 300 亿元人民币，授权期限自公司 2023 年度股 东大会审议通过之日起至下一年度股东大会召开时止。具体内容详见 刊登于巨潮资讯网（www.cninfo.com.cn）的《关于公司及子公司向银 行申请授信额度及担保事项的公告》《2023 年度股东大会决议公告》 （公告编号：2024-036、20 ...

Investment Rating - The report assigns a "Buy" rating for the company, Inco Medical, based on its potential to benefit from the recovery of nitrile glove prices and its position as a global leader in disposable glove production [3]. Core Views - The nitrile glove prices have stabilized and are on the rise, with a significant increase from a low of $15.26 per box in October 2023 to $17.99 per box by October 2024. This recovery is attributed to the exit of high-cost production capacities and the aging of Malaysian production facilities [1][34]. - Inco Medical has become a leading disposable glove manufacturer globally, with a total capacity of 87 billion gloves, including 56 billion nitrile gloves, positioning it just behind Top Glove in terms of production capacity but ahead in revenue [2][27]. - The company is expected to see substantial growth in net profit, with projections for 2024 indicating a net profit of 1.2 to 1.5 billion yuan, representing a year-on-year increase of approximately 213% to 292% [1]. Summary by Sections 1. Glove Industry Overview - The disposable medical glove industry is experiencing a rebound, with nitrile gloves becoming the main product in the incremental market due to their superior properties compared to PVC and latex gloves [13]. - The global sales volume of nitrile gloves is projected to grow at a CAGR of 11.6% from 2022 to 2025, outpacing the overall glove market growth [23]. 2. Nitrile Glove Price Recovery - Nitrile glove prices have shown a recovery trend since February 2024, with the average export price increasing from $15.26 per box in October 2023 to $17.99 per box in October 2024 [1][34]. - The price of nitrile latex, a key raw material for glove production, has also risen, contributing to the potential for price increases in end products [38]. 3. Company Position and Performance - Inco Medical's production capacity is significant, with 870 million gloves produced, making it a leader in the industry. The company has also established a strong upstream material supply chain by holding stakes in several nitrile latex production companies [2][27]. - The company's revenue for 2024 is projected to be approximately 9.43 billion yuan, with a year-on-year growth rate of 36.3% [5]. 4. Financial Forecast and Valuation - The financial forecast for Inco Medical indicates a net profit of approximately 1.33 billion yuan in 2024, with a projected PE ratio of around 12.7X for 2024 [3][5]. - The company is expected to maintain a competitive edge due to its scale, cost control, and upstream material layout, which are anticipated to drive continued profitability [3].